by David Eyre | Jan 22, 2024 | US & International
Background – Skinny Labelling Enacted by the Hatch–Waxman Act In 1984, the US Congress introduced a law called the Drug Price Competition and Patent Term Restoration Act, or the “Hatch–Waxman” Act after the two sponsors of the bill: Representative Henry Waxman and...
by Sean Hutchinson | Dec 21, 2023 | EPO
Our Headnote It seems that the era of “plausibility” is over, and there may now be little, if any, consideration given to whether the technical effect was plausible / not implausible in view of the application as filed. Instead, emphasis is now placed on the “broadest...
by Chloe Sullivan | Dec 20, 2023 | EPO
The case has now been remitted to the ED after it was found by the Board that several substantial procedural violations were committed. Below is our timeline of the examination procedure and it is safe to say that, after considering the facts, we are siding with the...
by George Schlich | Nov 21, 2023 | EPO, Uncategorised
Change in acceleration practice Recent changes to EPO opposition acceleration practice, published earlier this month, further expand the integration of EPO oppositions with post grant actions in court, whether at the Unified Patent Court or in a national court....
by Sean Hutchinson | Nov 7, 2023 | UK
Background Under UK law, if an invention is devised by a person who is an employee of another party, and that other party owns the invention by virtue of being that person’s employer then, if a patent is granted for the invention and either the invention or the patent...
Recent Comments